Nuvo Research announced the FDA has approved Mallinckrodt’s Pennsaid (diclofenac sodium) topical solution 2% w/w.

Pennsaid 2% is a topical nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of osteoarthritis pain of the knee.

RELATED: Musculoskeletal Disorders Resource Center

Diclofenac inhibits the enzyme, cyclooxygenase (COX), an early component of the arachidonic acid cascade, resulting in the reduced formation of prostaglandins, thromboxanes and prostacylin.

Continue Reading

Pennsaid 2% is a follow-on to the original Pennsaid 1.5% w/w that has been available since 2010.   The new 2% topical solution is more viscous than original Pennsaid 1.5%.

Pennsaid 2% topical solution is supplied in a metered dose pump bottle. Mallinckrodt plans to launch Pennsaid 2% in the first quarter of 2014.

For more information, call (888) 744-1414 or visit